ASTERIX: An observational study to identify sub-groups of COVID-19 patients based on their demographic, clinical and laboratory profile, and to determine if these sub-groups can be used to predict severity of disease and response to therapy

Adaptive Stratification of COVID-19 to facilitate Endotype-directed Intervention Studies (ASTERIX)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN66141262

Enrollment

600

Registered

2020-10-22

Start date

2020-01-01

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 (SARS-CoV-2 infection) Infections and Infestations COVID-19 (SARS-CoV-2 infection)

Interventions

The study aims to achieve the following: 1. Recruit between 600 and 1200 participants with appropriate approvals 2. To acquire and record the necessary biological and outcome data using direct electro

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Admitted to hospital with suspected COVID-19

Exclusion criteria

Exclusion criteria: 1. Aged <8 years (lower age limit aligns with current NHSGGC Biorepository REC approval for storage and use of surplus tissue)

Design outcomes

Primary

Measure	Time frame
To acquire and record the necessary biological and outcome data by extracting electronic medical records held by the NHS trust Safe Haven, collected at various timepoints by automated processes. Daily clinical data (e.g. oxygen requirement, clinical observations, vital status) will also be collected by ward staff using a bedside clinical collection tool embedded in clinical care daily clinical data (the NHSGGC COVID19 assessment tool). Biological materials (e.g. blood, respiratory secretions, urine) for potential translational research will be surplus material from that routinely collected during the hospital admission, and also any follow-up hospital visits within 1 year.	—

Measure

Time frame

To acquire and record the necessary biological and outcome data by extracting electronic medical records held by the NHS trust Safe Haven, collected at various timepoints by automated processes. Daily clinical data (e.g. oxygen requirement, clinical observations, vital status) will also be collected by ward staff using a bedside clinical collection tool embedded in clinical care daily clinical data (the NHSGGC COVID19 assessment tool). Biological materials (e.g. blood, respiratory secretions, urine) for potential translational research will be surplus material from that routinely collected during the hospital admission, and also any follow-up hospital visits within 1 year.

—

Secondary

Measure	Time frame
There are no secondary outcome measures	—

Countries

Scotland, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026